KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Halozyme Therapeutics (HALO) Receivables - Net (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Receivables - Net for 16 consecutive years, with $441.3 million as the latest value for Q4 2025.

  • Quarterly Receivables - Net rose 43.06% to $441.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $441.3 million through Dec 2025, up 43.06% year-over-year, with the annual reading at $441.3 million for FY2025, 43.06% up from the prior year.
  • Receivables - Net for Q4 2025 was $441.3 million at Halozyme Therapeutics, up from $346.0 million in the prior quarter.
  • The five-year high for Receivables - Net was $441.3 million in Q4 2025, with the low at $89.5 million in Q1 2021.
  • Average Receivables - Net over 5 years is $226.6 million, with a median of $224.2 million recorded in 2022.
  • The sharpest move saw Receivables - Net soared 313.15% in 2021, then dropped 12.86% in 2024.
  • Over 5 years, Receivables - Net stood at $92.1 million in 2021, then soared by 150.85% to $231.1 million in 2022, then rose by 1.36% to $234.2 million in 2023, then soared by 31.7% to $308.5 million in 2024, then soared by 43.06% to $441.3 million in 2025.
  • According to Business Quant data, Receivables - Net over the past three periods came in at $441.3 million, $346.0 million, and $316.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.